Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2024 | $16.50 | Buy | Lake Street |
7/16/2024 | $9.00 → $12.00 | Hold → Buy | Stifel |
11/28/2023 | $11.00 | Hold | Stifel |
8/4/2023 | $20.00 → $200.00 | Strong Buy → Outperform | Raymond James |
3/21/2023 | $5.50 → $10.00 | Buy → Hold | Jefferies |
3/7/2022 | $28.00 → $14.00 | Outperform | Cowen & Co. |
2/22/2022 | $28.00 → $23.00 | Strong Buy → Outperform | Raymond James |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Mizuho raised the price target for Microsoft Corporation (NASDAQ:MSFT) from $450 to $480. Mizuho analyst Gregg Moskowitz maintained an Outperform rating. Microsoft shares gained 0.1% to close at $453.96 on Monday. See how other analysts view this stock. HC Wainwright & Co. boosted the price target for Revolution Medicines, Inc. (NASDAQ:RVMD) from $44 to $56. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Revolution Medicines shares gained 1.9% to close at $46.00 on Monday. See ho
Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the price target from $9 to $12.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp
TORONTO, May 15, 2024 /CNW/ - Profound Medical Corp. (TSX:PRN) (NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 13,437,920 common shares, representing 63.64% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 6, 2023 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
- Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook Medical, shared their common vision with Profound of creating a total diagnostic and interventional MR solution for prostate disease - TORONTO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, was pleased to host its second ‘PRO-Talk Live!' event in Las Vegas this past Saturday, September 14, 20
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth "Big8" Conference on September 12, 2024 in New York City. The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available. About Profound Medical Corp. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free thera
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed base grew from 53 at the end of Q1-2024 to 57 as of the end of Q2-2024;
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed base grew from 53 at the end of Q1-2024 to 57 as of the end of Q2-2024;
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2024 Results Conference Call Details: Date: Thursday, August 8, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BIbfa8c9bee6c646
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed
6-K - Profound Medical Corp. (0001628808) (Filer)
S-8 - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)
Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50
Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously
Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00